Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma... RESE AR CH AR TICLE Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model 1,2,3 1 4 1 Camille Guillerey, Kyohei Nakamura, Andrea C. Pichler, Deborah Barkauskas, 1 1 1 2,5 1 1 Sophie Krumeich, Kimberley Stannard, Kim Miles, Heidi Harjunpää, Yuan Yu, Mika Casey, 6 7 8 8 9,10 Alina I. Doban, Mircea Lazar, Gunter Hartel, David Smith, Slavica Vuckovic, 5 11 11 9,12 4 Michele W.L. Teng, P. Leif Bergsagel, Marta Chesi, Geoffrey R. Hill, Ludovic Martinet, 1,2 and Mark J. Smyth Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, 2 3 Australia. School of Medicine, The University of Queensland, Herston, Queensland, Australia. Cancer Immunotherapies Laboratory, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, 4 5 Queensland, Australia. Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France. Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, 6 7 Australia. ASML Netherlands B.V., Veldhoven, Netherlands. Department of Electrical Engineering, Eindhoven 8 9 University of Technology, Eindhoven, Netherlands. Statistics Unit and Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. Multiple Myeloma Research Group, Institute of Haematology, Royal Prince http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCI Insight Unpaywall

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model

Download PDF
19 pages

Loading next page...
 
/lp/unpaywall/chemotherapy-followed-by-anti-cd137-mab-immunotherapy-improves-disease-WJdB0p2hjs

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Unpaywall
ISSN
2379-3708
DOI
10.1172/jci.insight.125932
Publisher site
See Article on Publisher Site

Abstract

RESE AR CH AR TICLE Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model 1,2,3 1 4 1 Camille Guillerey, Kyohei Nakamura, Andrea C. Pichler, Deborah Barkauskas, 1 1 1 2,5 1 1 Sophie Krumeich, Kimberley Stannard, Kim Miles, Heidi Harjunpää, Yuan Yu, Mika Casey, 6 7 8 8 9,10 Alina I. Doban, Mircea Lazar, Gunter Hartel, David Smith, Slavica Vuckovic, 5 11 11 9,12 4 Michele W.L. Teng, P. Leif Bergsagel, Marta Chesi, Geoffrey R. Hill, Ludovic Martinet, 1,2 and Mark J. Smyth Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, 2 3 Australia. School of Medicine, The University of Queensland, Herston, Queensland, Australia. Cancer Immunotherapies Laboratory, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, 4 5 Queensland, Australia. Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France. Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, 6 7 Australia. ASML Netherlands B.V., Veldhoven, Netherlands. Department of Electrical Engineering, Eindhoven 8 9 University of Technology, Eindhoven, Netherlands. Statistics Unit and Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. Multiple Myeloma Research Group, Institute of Haematology, Royal Prince

Journal

JCI Insight – Unpaywall

Published: Jul 25, 2019

There are no references for this article.